Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

Related Articles by Review for PubMed (Select 16901028)

1.

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA.

Mayo Clin Proc. 2006 Aug;81(8):1047-53. Review.

PMID:
16901028
2.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;5:CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
3.

Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Dhillon S, Lyseng-Williamson KA.

Drugs. 2008;68(4):507-34. Review.

PMID:
18318568
4.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.

Cancer Invest. 2002;20 Suppl 2:45-54. Review.

PMID:
12442349
5.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
6.

Bisphosphonate complications including osteonecrosis of the jaw.

Mehrotra B, Ruggiero S.

Hematology Am Soc Hematol Educ Program. 2006:356-60, 515. Review.

7.
8.

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Hamdy RC.

Drug Des Devel Ther. 2010 Nov 18;4:321-35. doi: 10.2147/DDDT.S6287. Review.

9.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
10.

The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Pozzi S, Raje N.

Oncologist. 2011;16(5):651-62. doi: 10.1634/theoncologist.2010-0225. Epub 2011 Apr 14. Review.

11.
12.

Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.

Phillips JM, Thibodeaux JD, Nathan C.

Laryngoscope. 2010;120 Suppl 4:S175. doi: 10.1002/lary.21639. Review.

PMID:
21225773
13.

Adverse effects of bisphosphonates: current issues.

Diel IJ, Bergner R, Grötz KA.

J Support Oncol. 2007 Nov-Dec;5(10):475-82. Review.

PMID:
18240669
14.

[Bisphosphonates for myeloma patients].

Miwa A.

Nihon Rinsho. 2007 Dec;65(12):2315-37. Review. Japanese.

PMID:
18069279
15.

Bisphosphonates in multiple myeloma.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD003188. doi: 10.1002/14651858.CD003188.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD003188.

PMID:
20238320
16.

Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.

Body JJ.

Expert Opin Pharmacother. 2003 Apr;4(4):567-80. Review.

PMID:
12667119
17.

Zoledronic acid in the management of metastatic bone disease.

Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G.

Expert Opin Biol Ther. 2006 Dec;6(12):1333-48. Review.

PMID:
17223741
18.

Role of zoledronic acid in the prevention and treatment of osteoporosis.

Räkel A, Boucher A, Ste-Marie LG.

Clin Interv Aging. 2011;6:89-99. doi: 10.2147/CIA.S7282. Epub 2011 Mar 28. Review.

19.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
20.

Bisphosphonate-related osteonecrosis of the jaw: an overview.

Ruggiero SL.

Ann N Y Acad Sci. 2011 Feb;1218:38-46. doi: 10.1111/j.1749-6632.2010.05768.x. Epub 2010 Sep 28. Review.

PMID:
20946580
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk